Calviri

Imagine explaining to your grandkids what cancer was- because it didn’t exist. Calviri created technologies that can make that happen. Our mission is to end cancer worldwide, and we know how to do it.

A 5 year, 800 dog trial testing a preventative cancer vaccine has been completed. There was a 40% reduction in tumor incidence in the vaccinated dogs. A trial testing a canine therapeutic immunologic is ongoing. The manufacture and assay systems are in place to begin sales of our canine cancer diagnostic test in August, 2025.

Cancer remains a leading cause of death worldwide, even in the face of enormous research and clinical efforts. These have yielded some promising therapies; however, they are neither broadly effective nor affordable. The physical and emotional costs of cancer cannot be quantified; however, incidence and death can. Cancer kills 10M people annually, worldwide. The estimated global cost of cancer from now to 2050 is more than $25 trillion. There is a cancer crisis.

Calviri has developed a universal diagnostic chip that can detect cancer at stage 1. This saves lives even with standard of care. This chip can be used to diagnose cancer in addition to other diseases in both people and dogs. We have discovered a new source of neoantigens that can be used to create immunotherapeutics to treat or even prevent cancer. Products will be affordable worldwide, for both people and their pets.

Calviri is a holding company for spinoffs for Companion Animal Diagnostics, Companion Animal Immunologics, Human Diagnostics, Human Immunologics and Calviri Technologies.
Our current focus is on the Companion Animal Diagnostics (CAD), bringing our first product to market in August, 2025. CAD will be develop independently or be acquired.

GSD Superscaler
Venture Madness